Infarmed Reads SNS Medicine Spend at a Record €4.417 Billion in 2025 — Hospital Drugs Cross €2.5 Billion for the First Time as Oncology Adds €864.5 Million at +16% and Ambulatory Comparticipação Lifts to €1.894 Billion at +12.4%

The Serviço Nacional de Saúde spent a record €4,417 million on medicines in 2025, according to the Infarmed monitor whose summary tables hit the wires on Tuesday 19 May 2026. The headline is +60% above the 2020 pandemic baseline of €2,759 million and the first time the combined hospital + ambulatory comparticipação line has crossed €4.4 billion. Lusa carries the data; RTP, Jornal de Negócios and Público run it as their lead Tuesday-morning health beat.

The two engines, broken out

Hospital medicines lifted to €2,523 million in 2025 — a +11.2% step-up and the first print above €2.5 billion in the series. Ambulatory comparticipação — the state's contribution to retail-pharmacy prescriptions — closed at €1,894 million, up 12.4% on 2024. Both engines posted double-digit growth for the fourth year running; the 2020-2025 cumulative for the hospital book is closer to +90%.

The hospital number carries a heavy concentration: oncology drugs alone landed at €864.5 million in 2025, up 16% year-on-year, and now represent roughly one-third of all hospital-medicine spend. Orphan drugs — the regulatory bucket for rare-disease therapies — added €465 million at +34.1%, the fastest-growing line in the entire 2025 file. HIV-treatment spend came in at €238.2 million; vaccines, a smaller bucket, jumped 69.8% to €85.5 million as the post-pandemic vaccination calendar normalised inside the SNS budget.

Q1 2026 already running ahead

The first-quarter 2026 hospital read is €693.4 million, +7.6% on Q1 2025 — slightly below the 2024-2025 cadence but still firmly in double-digit annualised territory once the back-end-of-year clinical-trial closures and innovative-therapy authorisations are factored in. The ambulatory Q1 2026 read for families lands at €243.1 million, +1.3% on Q1 2025, a sharp deceleration from the 2025 full-year +4.9% read that suggests the recent generics-share push is starting to bite at the household level.

What families paid out of pocket

Portuguese households spent €966 million on medicines in 2025, up 4.9% from €920.7 million in 2024. The Infarmed breakdown gives the average per-package out-of-pocket cost at €4.67 in Q1 2026 (-1.2% year-on-year), with the average SNS reimbursement at €9.60 (+6.9%) — the wedge between what the state pays and what the patient pays is widening, in the patient's favour, where comparticipação rules are being recalibrated upwards. Generic medicines accounted for 50.9% of all outpatient prescriptions in 2025, rising to 63.7% in therapeutic classes with available alternatives.

The drug-class mosaic

Antidislipidémicos — the cholesterol and triglyceride class led by atorvastatin — remain the single most-dispensed therapeutic line at 21.3 million packages in 2025, +9.7%. The top four active substances by package volume read: atorvastatina (8.5 million packages), paracetamol (4.8M), bisoprolol (3.9M) and metformina (3.4M). On the ambulatory comparticipação spend line, antidiabéticos lift to €478.9 million at +14.7% — a number that will be read alongside the parallel Government decision window on GLP-1 emagrecimento comparticipação that the Health Ministry committed to close next week.

Read across

The Infarmed monitor is the cleanest single-source read on SNS pharma run-rate; it lands ahead of the OPSS Primavera report due later in May and ahead of the OE2026 mid-year execution review. Three implications for the policy file already in motion:

• OE2026 envelope risk. If Q1 2026 hospitals run +7.6% and the 2025 full-year was +11.2%, the OE2026 medicines line — built on a conservative single-digit-growth assumption — has very little slack left for an oncology or orphan-drug authorisation tide in H2.
• EY-Parthenon read coherent. The 18 May private-health-coverage saving of €1.945 billion in 2023 is built on private insurers absorbing a portion of the same therapy mix that is driving the +16% oncology line; both readings point at innovative oncology and rare-disease therapies as the structural cost driver across both health systems.
• Drug-access pipeline pressure. The 18 May Lusa read on the 650-day average between EU authorisation and SNS funding decision now reads as a one-sided fiscal lever: the longer the delay, the more the pent-up demand pushes into the comparticipação book once the funding decision lands.

The full Infarmed series — including the therapeutic-class-by-therapeutic-class breakdown for 2025 — will land in the formal Monitorização Mensal report next week. The Q1 2026 update will be the first read of how the 2026 envelope is tracking against the OE assumption. On the Bial Phase 2 BIA 28-6156 discontinuation, Opicapone (Ongentys), Portuguese pharma R&D, SIFIDE II and CNS development pipeline side of the file, our 11 June read on Bial shelving the BIA 28-6156 Parkinson Phase 2 trial after the Trofa pharma read no efficacy signal at the primary endpoint, folding the five-year GBA1-targeted disease-modification programme while leaving the Opicapone (Ongentys) symptom-control franchise unaffected sets the latest reference.